Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A

Date 02 March 2015
Event 13th International Congress on Targeted Anticancer Therapies
Session Phase 1 studies: Miscellaneous drugs & targets
Topics Anti-Cancer Agents & Biologic Therapy
Drug Development
Presenter Lesley Seymour